Phase 3 Trial – Benlysta
Phase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis UPDATE 16/09/2020 In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone. The…
